Evaluation of Azathioprine versus Mycophenolate Mofetil as a Steroid Sparing Agent in the Treatment of Pemphigus Vulgaris
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background: Pemphigus vulgaris (PV) is a life-threatening autoimmune bullous disease characterized by flaccid blisters and erosions of the skin and mucous membranes due to acantholysis. The severity of diseases stems from their progressive nature, leading to increased body catabolism, loss of body fluids and proteins, and secondary bacterial and viral infections that can result in sepsis and cardiac failure. Objective: To compare the efficacies of azathioprine versus mycophenolate mofetil as a steroid-sparing agent in the treatment of pemphigus vulgaris. Methods: This comparative study was conducted in the Department of Dermatology and Venereology at Combined Military Hospital, Dhaka from April 2016 to September 2016. As the study subjects, 60 adult pemphigus vulgaris patients were enrolled and divided into two groups; Group A received oral mycophenolate mofetil (1.5 gm daily) for 12 weeks, while Group B received azathioprine (2.5 mg/kg/day) for the same period. Data were analyzed using SPSS v23.0. Results: Baseline sociodemographic and clinical characteristics were similar between Group A and Group B, with no significant differences in age, sex, marital status, disease duration or family history of pemphigus vulgaris. Both groups exhibited progressive clinical improvement over time. Group A achieved a significantly greater reduction in mean PDAI score at 12 weeks (14.2±7.1 vs 19.7±8.4, p=0.008) and at 24 weeks (6.8±5.9 vs 12.4±7.0, p=0.001). Mean severity scores declined in both groups, with lower final scores observed in Group A (0.57±0.76 vs 1.00±0.96), although this difference did not reach statistical significance (p=0.059). Adverse effects were reported in both groups, with gastrointestinal disturbances more prevalent in Group A and hematologic complications more frequent in Group B. Conclusion: Mycophenolate mofetil is slightly more efficacious than azathioprine. It can serve as a good alternative for the treatment of pemphigus vulgaris as a steroid-sparing agent, provided the individual can afford this drug due to its high cost and relatively fewer side effects. JAFMC Bangladesh, Vol-22, No-1, June 2026:23-27
Author: Md Moshiur Rahman
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7225881073
